356 related articles for article (PubMed ID: 11343220)
1. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.
Dornadula G; Nunnari G; Vanella M; Roman J; Babinchak T; DeSimone J; Stern J; Braffman M; Zhang H; Pomerantz RJ
J Infect Dis; 2001 Jun; 183(11):1682-7. PubMed ID: 11343220
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients.
Re MC; Vitone F; Biagetti C; Schiavone P; Alessandrini F; Bon I; de Crignis E; Gibellini D
Clin Microbiol Infect; 2010 Jun; 16(6):640-6. PubMed ID: 19732081
[TBL] [Abstract][Full Text] [Related]
3. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
Carr JM; Cheney KM; Coolen C; Davis A; Shaw D; Ferguson W; Chang G; Higgins G; Burrell C; Li P
J Clin Microbiol; 2007 Apr; 45(4):1288-97. PubMed ID: 17314225
[TBL] [Abstract][Full Text] [Related]
4. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.
Kulkosky J; Nunnari G; Otero M; Calarota S; Dornadula G; Zhang H; Malin A; Sullivan J; Xu Y; DeSimone J; Babinchak T; Stern J; Cavert W; Haase A; Pomerantz RJ
J Infect Dis; 2002 Nov; 186(10):1403-11. PubMed ID: 12404155
[TBL] [Abstract][Full Text] [Related]
7. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies.
Tebas P; Henry K; Mondy K; Deeks S; Valdez H; Cohen C; Powderly WG
J Infect Dis; 2002 Sep; 186(6):851-4. PubMed ID: 12198623
[TBL] [Abstract][Full Text] [Related]
8. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
[TBL] [Abstract][Full Text] [Related]
9. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
10. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
11. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of total and integrated HIV-1 DNA in peripheral CD4 lymphocytes and monocytes after long treatment with HAART.
Calcaterra S; Cappiello G; Di Caro A; Garbuglia AR; Benedetto A
J Infect; 2001 Nov; 43(4):239-45. PubMed ID: 11869061
[TBL] [Abstract][Full Text] [Related]
13. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.
Zhang H; Dornadula G; Beumont M; Livornese L; Van Uitert B; Henning K; Pomerantz RJ
N Engl J Med; 1998 Dec; 339(25):1803-9. PubMed ID: 9854115
[TBL] [Abstract][Full Text] [Related]
14. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
[TBL] [Abstract][Full Text] [Related]
15. Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes.
Kaiser P; Joos B; Niederöst B; Weber R; Günthard HF; Fischer M
J Virol; 2007 Sep; 81(18):9693-706. PubMed ID: 17609262
[TBL] [Abstract][Full Text] [Related]
16. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
Soulié C; Marcelin AG; Ghosn J; Amellal B; Assoumou L; Lambert S; Duvivier C; Costagliola D; Katlama C; Calvez V
AIDS; 2007 Oct; 21(16):2243-5. PubMed ID: 18090053
[TBL] [Abstract][Full Text] [Related]
18. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
Pomerantz RJ
Clin Infect Dis; 2002 Jan; 34(1):91-7. PubMed ID: 11731950
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
Stone SF; Price P; French MA
HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
[TBL] [Abstract][Full Text] [Related]
20. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.
Flynn PM; Rudy BJ; Douglas SD; Lathey J; Spector SA; Martinez J; Silio M; Belzer M; Friedman L; D'Angelo L; McNamara J; Hodge J; Hughes MD; Lindsey JC;
J Infect Dis; 2004 Jul; 190(2):271-9. PubMed ID: 15216461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
